



The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023

Stockholm, Sweden - August 22, 2023 - Today is the last day of trading in warrants series TO2 in Biosergen AB ("Biosergen" or the "Company"). The exercise period for the warrants series TO2 runs up until August 25, 2023. Each warrant series TO2 gives the owner the right to subscribe for one (1) new share in the Company at an exercise price of SEK 0.66 per share.

If all warrants series TO2 are exercised, the Company will receive approximately SEK 5.7 million before issuing costs. In order for the warrants not to expire and lose their value, it is required that the holder actively subscribes for new shares no later than August 25, 2023, or sells the warrants no later than August 22, 2023. Please observe that certain nominees might close their application earlier than August 25, 2023.

Summarized terms for warrants series TO2:

Exercise period: August 14 – August 25, 2023.

Issue size: 8,595,531 warrants series TO2, which entitle to subscription of 8,595,531 shares. If all warrants are exercised, the Company will receive approximately SEK 5.7 million before issuing costs.

Subscription price: SEK 0.66 per share.

Last day for trading warrants series TO2: August 22, 2023.

Share capital and dilution: If all warrants are exercised, the share capital will increase with SEK 214,888.275, from SEK 1,060,691.500 to SEK 1,275,579.775, and the number of shares and votes in the Company will increase with 8,595,531, from 42,427,660 to 51,023,191. In the event that all warrants series TO2 are exercised, the dilution amounts to approximately 16.8 percent of the number of shares and votes in the Company.

Please note that warrants that are not exercised no later than August 25, 2023, or sold no later than August 22, 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised:

Nominee-registered warrants (Custody account)

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Note that the nominees need your notification of the exercise of warrants series TO2 in time before the end of the exercise period. Please contact your nominee for additional information. Observe that certain nominees might close their application earlier than August 25, 2023.

Direct-registered warrants (Securities account)

The warrant holders who have warrants series TO2 in a VP-account subscribe directly via an application form. The application form is then to be submitted via e-mail to emissioner@mangold.se or by mail according to instructions on the application form. Please contact the institute where you have your warrants registered for additional information.

The application form including instructions for payment will be available at the Company's website, www.Biosergen.net.

Advisors

Mangold Fondkommission AB is the financial advisor and Setterwalls Advokatbyrå AB is the legal advisor to Biosergen in connection with the exercise of warrants series TO2.

For further information about Biosergen, please contact:

Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net

Niels Lauren, CFO
Telephone: +45 4014 5059
E-mail: niels.laursen@biosergen.net

Certified Adviser

Erik Penser Bank
Telephone: +46 8 463 8000
E-mail: certifiedadvisor@penser.se

ABOUT BIOSERGEN

Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to Phase II clinical trials expected to clinically validate BSG005's potential as a game-changing antifungal treatment. Biosergen's development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit www.biosergen.net.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Biosergen. Invitation to the persons concerned to subscribe for units consisting of shares and warrants in Biosergen has only taken place through the prospectus that Biosergen published on September 13, 2022.